Status:
COMPLETED
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse ...
Detailed Description
A total sample size of 160 to 200 HCPs and 160 to 200 patients
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Inclusion Criteria:
- HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose
Exclusion
Key Trial Info
Start Date :
July 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT02224768
Start Date
July 1 2015
End Date
November 1 2015
Last Update
December 21 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bristol-Myers Squibb
Princeton, New Jersey, United States, 08540
2
Local Institution
St Ives, Cambridgeshire, United Kingdom, PE27 5BZ